Dutch biotech Anaheim Bio, a spin-out of BioMarin-acquired Alesta Therapeutics, has launched with an oversubscribed €40 million Series A to advance ANA-1, a potential disease-modifying treatment for calcium pyrophosphate deposition disease (CPPD), commonly known as pseudogout, into clinical trials in 2027.
ADVERTISEMENT
Tag Archive for: arthritis
Forbion has spearheaded a €75m Series A financing in Norwegian biotech Calluna Pharma. The clinical-stage company resulted from the merger of Oxitope Pharma and Arxx Therapeutics.



